This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GMDAQ Gamida Cell (GMDAQ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Gamida Cell Stock (NASDAQ:GMDAQ) 30 days 90 days 365 days Advanced Chart Get Gamida Cell alerts:Sign Up Key Stats Today's Range$0.0160▼$0.018350-Day Range$0.0170▼$0.017052-Week Range$0.01▼$2.51Volume332,754 shsAverage Volume6.58 million shsMarket Capitalization$2.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Gamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company's product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and internationally. Gamida Cell Ltd. is headquartered in Jerusalem, Israel. Read More Receive GMDAQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter. Email Address GMDAQ Stock News HeadlinesAplastic Anemia Market to Witness Significant Growth by 2034, Fueled by Rising Prevalence and a Strong Pipeline | DelveInsightMay 15, 2025 | theglobeandmail.comGamida Cell Ltd. (GMDAQ)May 16, 2024 | finance.yahoo.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 17 at 2:00 AM | Crypto 101 Media (Ad)Gamida Cell has a second chance to be an Israeli success storyMay 12, 2024 | msn.comGMDAQ Gamida Cell Ltd.May 8, 2024 | seekingalpha.comGamida Cell Ltd.April 10, 2024 | wsj.comSee More Headlines Company Calendar Today8/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GMDAQ CIK1600847 Webwww.gamida-cell.com Phone617-892-9080FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63 million Net MarginsN/A Pretax Margin-2,317.95% Return on EquityN/A Return on Assets-60.18% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.33 Sales & Book Value Annual Sales$1.78 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-0.85Miscellaneous Outstanding Shares154,050,000Free Float143,699,000Market Cap$2.62 million OptionableOptionable Beta1.30 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:GMDAQ) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gamida Cell Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gamida Cell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access